Abstract 4364163: Polygenic Risk Score for Abdominal Aortic Aneurysm in Patients with Cardiometabolic Disease: Analysis of 40,000 Patients from 3 TIMI Trials
Abstract
Background: Abdominal aortic aneurysm (AAA) is a common and potentially fatal condition when rupture occurs. Current US guidelines recommend screening by ultrasound in men aged 65–75 with a smoking history. However, AAA remains underdiagnosed using these limited clinical criteria, underscoring the need to explore additional risk factors. We evaluated whether the addition of a polygenic risk score (PRS) for AAA helps identify individuals at higher risk among patients with established cardiometabolic disease. Methods: A genetic analysis was performed by pooling individual patient-level data from 3 TIMI trials (FOURIER, ENGAGE-AF and PEGASUS). AAA events were reported by investigators as adverse events, and blinded study physicians independently reviewed and confirmed all cases. We utilized a recently validated AAA PRS (Nat Genet, 2023) and assessed its association with AAA using Cox proportional hazard models adjusted for age, sex, smoking, history of ASCVD, HTN, hyperlipidemia, DM, trial and ancestry (PC1–5). PRS was analyzed continuously (per 1-SD) and categorically (high [top 20%], intermediate [middle 60%], low [bottom 20%]). Results: A total of 39,960 patients were included (median f/u 2.6 years). Individuals in higher PRS categories had a higher rate of AAA events over time ( Figure 1A ). Even after adjusting for clinical risk factors, a 1-SD higher PRS was independently associated with a 54% higher risk of AAA (HR-adj 1.54 [95% CI 1.35–1.76], p<0.001). Compared with low PRS, an intermediate PRS was associated with a 2-fold risk (HR-adj 2.03 [1.23–3.34], p<0.001), and a high PRS with a 3-fold risk (HR-adj 3.12 [1.82–5.36], p<0.001). The magnitude of risk conferred by a high PRS was comparable to traditional clinical risk factors ( Figure 1B ). Coclusion: In patients with cardiometabolic disease, an AAA PRS was independently associated with risk of AAA events, with a magnitude of risk on par with traditional clinical risk factors.
Article Details
Authors (12)
Yi-Pin Lai
TIMI Study Group, Boston, Massachusetts, United States
Samer Al Said
Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA (S.A.S., E.B., M.G.P., G.E.M.M., C.T.R., E.M.A., R.P.G.).
Giorgio Melloni
TIMI Study Group, Boston, Massachusetts, United States
Frederick Kamanu
TIMI Study Group, Boston, Massachusetts, United States
Robert Giugliano
TIMI Study Group, Boston, Massachusetts, United States
Elliott Antman
TIMI Study Group, Boston, Massachusetts, United States
Eugene Braunwald
TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Boston
Patrick Ellinor
The Broad Institute, Cambridge, Massachusetts, United States
Marc Bonaca
Marc Sabatine
TIMI Study Group, Boston, Massachusetts, United States
Christian Ruff
Nicholas Marston